Trials / Completed
CompletedNCT03239223
Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection
A Randomised, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate Safety, Tolerability and Pharmacokinetics of Topical ABI-1968 in Subjects With Cervical High Grade Squamous Intreaepithelial Lesions (cHSIL)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Antiva Biosciences · Industry
- Sex
- Female
- Age
- 25 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the use of topical ABI-1968 cream, in the treatment of cervical precancerous lesions in adult women.
Conditions
- HSIL
- HSIL of Cervix
- High-Grade Squamous Intraepithelial Lesions
- High-grade Cervical Intraepithelial Neoplasia
- Human Papilloma Virus
- Cervical Cancer
- Cervical Intraepithelial Neoplasia
- Cervical Neoplasm
- Cervical Dysplasia
- CIN
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABI-1968 | Topical ABI-1968 Cream or Placebo with 4 doses administered up to 4 Cohorts |
Timeline
- Start date
- 2018-01-01
- Primary completion
- 2018-10-30
- Completion
- 2018-10-30
- First posted
- 2017-08-03
- Last updated
- 2019-07-10
Locations
9 sites across 2 countries: United States, Australia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03239223. Inclusion in this directory is not an endorsement.